🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Complete findings from the ORCA-3 Phase 3 trial published in JAMA Internal Medicine underscore the potential to address nicotine dependence and support individuals on their journey to quit smoking. Read more at bit.ly/ORCA3-JAMA-IM.

Millions are affected by smoking every year, but medical treatment options are still limited. Today, STAT spotlights our work towards a new solution in smoking cessation. Read the full story: bit.ly/4jTUXgT

Explore the latest research from Achieve Life Sciences in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. Join us at #ATS2025 to dive deeper into our findings. Read the abstract here: bit.ly/4d6g2T5

Published in JAMA Internal Medicine: More adults receiving 6- or 12-week #cytisinicline vs. placebo achieved #smoking abstinence🚭 in the last 4 weeks of treatment. healio.com/news/pulmonolo…

Check out this article from Healio Pulmonology for a breakdown of our Phase 3 ORCA-3 trial results, with comment from co-author of the study, Dr. Nancy Rigotti.

Save the Date! The American Thoracic Society (ATS) International Conference is coming up – hear from thousands of clinicians and researchers, including our Head of Medical Affairs, Dr. Mark Rubinstein Will you be attending #ATS2025? Let us know!

Achieve Life Sciences has released our Q1 2025 earnings report. Read the full press release at bit.ly/3SyPUXy and join us on our call at 8:30 AM ET to learn more at bit.ly/3GTJNdS

Today, we presented our Q1 earnings report and shared updates on clinical progress, major milestones, and our mission to address nicotine dependence. Read more at bit.ly/3SyPUXy and watch a summary of the call directly from CEO Rick Stewart at bit.ly/3H5oWUU.

Don’t miss Dr. Mark Rubinstein’s presentation on new data from our Phase 3 studies at the American Thoracic Society (ATS)’s International Conference! Learn how cytisinicline, our investigational treatment, is advancing smoking cessation research. #ATS2025

We’re thrilled to be in San Francisco, attending the American Thoracic Society (ATS)’s International Conference! Are you attending #ATS2025? If you’re interested in meeting with us, please send an email to [email protected].

Today, Achieve Life Sciences will present new data from our Phase 3 ORCA-3 trial results during an oral session at the 2025 American Thoracic Society (ATS)’s International Conference. For more details, read the full press release: bit.ly/AchieveATS2025 #ATS2025

We’re excited to announce that Achieve Life Sciences will participate in the Jefferies Global Healthcare Conference. We’ll share updates on our progress addressing nicotine dependence as a treatment for smoking cessation. Read more at bit.ly/AchieveJefferi…

The ORCA-3 Phase 3 trial results for our investigational treatment, cytisinicline, recently published in JAMA Internal Medicine, highlighted the need for new treatment options. What do you think is the biggest challenge to quitting smoking? Read more: bit.ly/ORCA3-JAMA-IM

Join us today at 5:30 PM ET as our CEO, Rick Stewart, presents Achieve Life Sciences' efforts to address nicotine dependence and support individuals on their journey to quit smoking. Watch the live webcast and recording at: ir.achievelifesciences.com

Recently, our CEO, Rick Stewart, joined Justin Walsh, Director, Research Analyst at JonesTrading, to discuss the critical need for innovation in the smoking cessation market and how Achieve is working to address nicotine dependence. Register and watch the full recording at

Today, Achieve announced that it has submitted a New Drug Application to the U.S. FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation. We are thrilled to have taken this next step. Read more: bit.ly/AchieveNDA

With Omnicom, we've outlined a launch strategy for the first potential new treatment for nicotine dependence in 20 years. With proven, cross-industry insights, we aim to set a new standard for biotech and help millions who want to quit. Learn more: bit.ly/AchieveOmnicom

Achieve Life Sciences announces pricing of $45.0 million underwritten public offering. Learn more: bit.ly/4nopGW2

A new feature in @MMNews dives into Achieve’s partnership with Omnicom, with insights from our CCO. We look forward to working with Omnicom to create a new standard for biopharma launches in preparation for the launch of our potential smoking cessation treatment. Learn more: